Pharma BD Deal Intelligence

Celgene Corporation / Avila Therapeutics, Inc.

2012 · Acquisition/Merger · $925M · Complete

Announcement Sentiment

Strongly positive

Celgene acquired Avila Therapeutics for $350M upfront plus up to $575M in milestones tied to AVL-292 ($195M) and Avilomics platform candidates ($380M). Expanded Celgene's hematologic cancer pipeline with covalent BTK inhibition.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Dilutive

Pipeline outcome

Assets Terminated

Assessment window: 10yr post-close.

Key facts

Announced Jan 26, 2012
Closed Mar 08, 2012
Deal value $925M
Deal type Acquisition/Merger
Therapeutic area Hematologic cancers (NHL, CLL) and autoimmune disease
Indications Hematologic cancers (NHL, CLL) and autoimmune disease
Key assets AVL-292 (CC-292) - covalent BTK inhibitor
Mechanism Selective covalent Bruton's tyrosine kinase (BTK) inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals